ï»¿<!DOCTYPE html ><html><body><div>H-0528.1</div><hr style="margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;" /><div style="font-weight:bold;text-align:center;">HOUSE BILL 1425</div><hr style="margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;" /><table style="width:622px;margin-top:0.1in;"><tr><td><div style="font-weight:bold;">State of Washington</div></td><td><div style="font-weight:bold;">69th Legislature</div></td><td><div style="font-weight:bold;">2025 Regular Session</div></td></tr></table><div style="margin-top:0.1in;"><span style="font-weight:bold;margin-right:0.25in;">By</span><!-- field: Sponsors -->Representatives Davis, Obras, Rule, Stonier, Parshley, Macri, Tharinger, Simmons, Berry, Gregerson, Doglio, and Ormsby<!-- field: --></div><div style="margin-top:0.1in;"><span style="margin-right:0.25in;">Read first time 01/20/25.</span><span style="margin-right:0.25in;">Referred to Committee on Health Care &amp; Wellness.</span></div><div style="text-indent:0.5in;margin-top:0.5in;"><!-- field: CaptionsTitles -->AN ACT Relating to requiring coverage of pharmacogenomic testing for psychotropic medications; reenacting and amending RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05.017'>41.05.017</a>; adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW; adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=74.09'>74.09</a> RCW; and creating a new section.<!-- field: --></div><div style="margin-top:0.25in;margin-bottom:0.25in;">BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:</div><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 1.  </span><span style="text-indent:0.5in;">(1) The legislature finds that mental health disorders are treatable conditions. When a patient has rapid access to the right medication, recovery is not only possible, it is probable. The vast majority of psychotropic medications are prescribed in primary care settings. Prescribers have little direction regarding which medication might be best for a particular patient. Due to this lack of precision, two-thirds of patients seeking treatment for depression do not improve with the first medication they try. Patients with mental health challenges are already at elevated risk for suicide, and many begin to feel increasingly hopeless as this haphazard process of medication trial and error continues with no symptom relief. Pharmacogenomic testing brings the best available science to bear in assisting health care providers in prescribing medications that are most likely to result in symptom remission for a given patient, while minimizing side effects. Such testing has been demonstrated to reduce psychiatric hospitalizations by nearly 40 percent. Many patients who have benefited from pharmacogenomic testing describe it as "life-changing" and indicate that they finally feel better after years of struggling on the wrong medications. Individuals who are courageously battling mental health challenges deserve the best possible chance at recovery via fast, effective treatment.</span><!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(2) Therefore, it is the intent of the legislature to require insurance coverage for pharmacogenetic testing for psychotropic medications without prior authorization and without requiring patients to first experience a treatment medication "failure."</div><!-- field: --><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 2.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(1) For health plans issued or renewed on or after January 1, 2026, a health carrier shall provide coverage for pharmacogenetic testing for psychotropic medications.</div><div style="text-indent:0.5in;">(2) A health carrier may not impose prior authorization or step therapy requirements to coverage required under this section.</div><div style="text-indent:0.5in;">(3) The pharmacogenetic testing for psychotropic medications must be covered when the testing is supported by medical and scientific evidence including, but not limited to:</div><div style="text-indent:0.5in;">(a) Tests approved or cleared by the United States food and drug administration;</div><div style="text-indent:0.5in;">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style="text-indent:0.5in;">(c) Nationally recognized clinical practice guidelines; </div><div style="text-indent:0.5in;">(d) Clinical trials and research studies; or</div><div style="text-indent:0.5in;">(e) Consensus statements.</div><div style="text-indent:0.5in;">(4) For purposes of this section:</div><div style="text-indent:0.5in;">(a) "Consensus statements" means statements that are:</div><div style="text-indent:0.5in;">(i) Developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict of interest policy;</div><div style="text-indent:0.5in;">(ii) Aimed at specific clinical circumstances; and</div><div style="text-indent:0.5in;">(iii) Based on the best available evidence for the purpose of optimizing the outcomes of clinical care.</div><div style="text-indent:0.5in;">(b) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that:</div><div style="text-indent:0.5in;">(i) Are developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy;</div><div style="text-indent:0.5in;">(ii) Establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options; and</div><div style="text-indent:0.5in;">(iii) Include recommendations intended to optimize patient care.</div><div style="text-indent:0.5in;">(c) "Pharmacogenetic testing" means the analysis of a patient's biospecimen for the presence of clinically significant genes or genetic variations that may impact how patients metabolize or respond to certain medications. Pharmacogenetic testing for purposes of this section includes single-gene and multigene tests.</div><!-- field: --><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="font-weight:bold;padding-right:0.1in;">Sec. 3.  </span>RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05.017'>41.05.017</a> and 2024 c 251 s 5 and 2024 c 242 s 10 are each reenacted and amended to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->Each health plan that provides medical insurance offered under this chapter, including plans created by insuring entities, plans not subject to the provisions of Title <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48'>48</a> RCW, and plans created under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05.140'>41.05.140</a>, are subject to the provisions of RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.500'>48.43.500</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.02.045'>70.02.045</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.505'>48.43.505</a> through  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.535'>48.43.535</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.537'>48.43.537</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.545'>48.43.545</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.550'>48.43.550</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.02.110'>70.02.110</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.02.900'>70.02.900</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.190'>48.43.190</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.083'>48.43.083</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.0128'>48.43.0128</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.780'>48.43.780</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.435'>48.43.435</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.815'>48.43.815</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.200.020'>48.200.020</a> through  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.200.280'>48.200.280</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.200.300'>48.200.300</a> through  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.200.320'>48.200.320</a>,  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43.440'>48.43.440</a>, <span style="text-decoration:underline;">section 2 of this act,</span> and chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.49'>48.49</a> RCW.<!-- field: --></div><!-- field: --><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 4.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=74.09'>74.09</a> RCW to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(1) By January 1, 2026, the authority and medicaid managed care organizations shall provide coverage for pharmacogenetic testing for psychotropic medications.</div><div style="text-indent:0.5in;">(2) The authority and medicaid managed care organizations may not impose prior authorization or step therapy requirements to coverage required under this section.</div><div style="text-indent:0.5in;">(3) The pharmacogenetic testing for psychotropic medications must be covered when the testing is supported by medical and scientific evidence including, but not limited to:</div><div style="text-indent:0.5in;">(a) Tests approved or cleared by the United States food and drug administration;</div><div style="text-indent:0.5in;">(b) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;</div><div style="text-indent:0.5in;">(c) Nationally recognized clinical practice guidelines; </div><div style="text-indent:0.5in;">(d) Clinical trials and research studies; or</div><div style="text-indent:0.5in;">(e) Consensus statements.</div><div style="text-indent:0.5in;">(4) For purposes of this section "consensus statements," "nationally recognized clinical practice guidelines," and "pharmacogenetic testing" have the same meanings as defined in section 2 of this act.</div><div style="text-indent:0.5in;">(5) In administering this program, the authority must seek any available federal financial participation under the medical assistance program, as codified at Title XIX of the federal social security act, the state children's health insurance program, as codified at Title XXI of the federal social security act, and any other federal funding sources that are now available or may become available.</div><!-- field: --><div style="margin-top:0.1in;font-weight:bold;text-align:center;">--- END ---</div></body></html>